Chemotherapies are being replaced on a large scale by novel antibody therapies. Improvements in viral vector manufacturing, plasmid DNA production and gene therapies make it possible to cure diseases that are still considered incurable today. And biologics are helping us manage viral and bacterial infections like RSV and Lyme disease.
Single Use Support is at the heart of the development and production of these medicines. Thanks to innovative solutions for the safe handling of pharmaceuticals, more and more renowned companies around the world are relying on technologies from Kufstein.
Problem solver
In the development and production of novel drugs, biotechnology companies are increasingly facing challenges in the process chain and in the handling of liquid drugs. After all, great importance is attached to making the process as efficient as possible and with low product losses. To achieve this, more and more use is being made of single-use support.
By automating the filling, freezing, storage and transport of liquids, complex process steps can be optimised and adapted to the respective customer requirements for the benefit of the patient.
Global expansion
Single Use Support continuously receives new major orders from the US, Europe and Asia. These come both from existing customers, in order to further expand the use of the technologies, and from new customers, who rely on the company from Tyrol for new active ingredients.
With sites in Kufstein, Hall in Tyrol and, from the end of 2023, also in Boston, Massachusetts, the company is already positioning itself for further growth in the coming years. At all locations, employees are sought who want to contribute to the development of new therapies to advance the healing of diseases.